Clinical trials: Advanced Non-squamous Non-Small-Cell Lung Cancer
- Condition Advanced Non-squamous Non-Small-Cell Lung Cancer
- Funder type Industry (pharma, biotech, devices)
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
This is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating docetaxel plus plinabulin versus docetaxel plus placebo in participants with advanced or metastatic non-squamous non-small cell…
- Trial name
- NCT07361484
- Testing
- Plinabulin, Docetaxel
- Volunteers
- 442 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Squamous-cell Non-Small-cell Lung Cancer
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
This is a phase 3 double-blinded randomized multicenter clinical trial of SCT-I10A or placebo plus docetaxel with previously treated squamous cell non-small cell lung cancer patients.
- Trial name
- NCT04171284
- Testing
- SCT-I10, Docetaxel
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Sinocelltech Ltd.
Non-Small Cell Lung Cancer
A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of bevacizumab (Avastin) versus placebo in combination with carboplatin/paclitaxel in participants with advanced or recurrent…
- Trial name
- NCT01364012
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 17 sites in China
- Volunteers
- 276 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- innovaTV 207 (NCT03485209)
- Testing
- tisotumab vedotin, pembrolizumab, carboplatin
- Where
- 175 sites in United States, Canada and 5 more
- Volunteers
- 350 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab…
- Trial name
- abound2L+ (NCT02250326)
- Testing
- nab-paclitaxel IV, CC-486, Duravalumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 240 people
- Sponsor
- Celgene
Non-small Cell Lung Cancer
Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer
This is a randomized, multicenter, open, controlled phase III trial. 388 subjects with stage IIIB who were not eligible for radical surgery or radiotherapy, stage IV or recurrent squamous cell NSCLC were enrolled in this study…
- Trial name
- NCT03262948
- Testing
- nab-paclitaxel, Paclitaxel, Carboplatin
- Volunteers
- 388 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Non Small Cell Lung Cancer
A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin…
- Trial name
- NCT00606021
- Testing
- pemetrexed, Best Supportive Care
- Where
- 5 sites in Egypt, Lebanon and 1 more
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer (NSCLC)
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC
- Trial name
- NCT00850577
- Testing
- Paclitaxel, Carboplatin, CT-322
- Where
- 55 sites in United States, Brazil and 6 more
- Volunteers
- 255 people
- Sponsor
- Bristol-Myers Squibb
Lung Neoplasms, Lung Cancer, Nonsmall Cell
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China
To evaluate the concordance of sensitizing mutations detected between paired plasma and tissue samples; the correlation between the clonal status of sensitizing mutations and targeted therapy response; and the prognostic impact…
- Conditions
- Lung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung, Squamous Cell Lung Cancer
- Trial name
- NCT03059641
- Where
- 14 sites in China
- Volunteers
- 300 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
NSCLC
Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC
A randomized, double blind, multicenter phase3 study .
- Trial name
- NCT02954172
- Testing
- Bevacizumab in Combination With Paclitaxel/Carboplatin, IBI305 in Combination with Paclitaxel/Carboplatin
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
A Study to Assess the Efficacy and Safety of ABTL0812
A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC.
- Trial name
- Endolung (NCT03366480)
- Testing
- ABTL0812 in combination with paclitaxel and carboplatin
- Where
- Spain
- Volunteers
- 103 people
- Sponsor
- Ability Pharmaceuticals SL
Non-Small Cell Lung Cancer
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to evaluate YL202 monotherapy versus Docetaxel in participants with locally…
- Trial name
- NCT07416994
- Testing
- YL202, Docetaxel
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B2033 alone or in combination with tislelizumab, with or without…
- Conditions
- Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
- Trial name
- NCT06427941
- Testing
- BGB-B2033, Tislelizumab, Bevacizumab
- Where
- 51 sites in United States, Brazil and 7 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC)
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in…
- Conditions
- Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT03811652
- Testing
- MEDI7247
- Where
- 3 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- MedImmune LLC
Non-Squamous Non-Small Cell Lung Cancer
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in…
- Trial name
- NCT06417008
- Testing
- HS-20117, Aumolertinib
- Where
- 2 sites in China
- Volunteers
- 1,080 people
- Sponsor
- Hansoh BioMedical R&D Company